Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-14 08:46Core Viewpoint - The announcement details the lifting of restrictions on a significant number of shares of Hualan Biological Engineering Co., Ltd., allowing for the circulation of 459 million shares, which accounts for 76.37% of the company's total share capital, effective from August 18, 2025 [2][5][23]. Group 1: Share Circulation Details - The restricted shares being released are part of the shares issued before the initial public offering (IPO) [2]. - The total number of shareholders involved in this release is two: Hualan Biological Engineering Co., Ltd. and Hong Kong Kecang Co., Ltd. [2][24]. - The total number of shares being released is 459,000,000, which represents 76.37% of the total share capital of the company [5][25]. Group 2: Share Capital Structure - As of the announcement date, the total share capital of the company is 601,027,500 shares, with 141,648,150 shares being unrestricted, accounting for 23.57% of the total [5]. - The company underwent a capital increase through a stock dividend distribution, resulting in an increase in total share capital from 400,010,000 shares to 600,015,000 shares [4]. Group 3: Compliance and Commitments - The shareholders lifting the restrictions have fulfilled their commitments made during the IPO process, ensuring compliance with relevant regulations [22]. - The commitments include not transferring or managing the shares for a specified period and adhering to regulations regarding share reduction [6][11]. Group 4: Clinical Trial Approval - Hualan Biological has received approval for clinical trials of its freeze-dried Hib vaccine, which is a significant step in its product development strategy [33]. - The vaccine aims to provide protection against invasive infections caused by Haemophilus influenzae type b, which is a major pathogen in children [34].